A clinical trial for frontotemporal dementia with GRN mutations
Information for people with FTD and their caregivers
AVIADOBIO: CHASING CURES. DELIVERING HOPE.™
At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
ASPIRE-FTD is an open-label, multi-center study designed to evaluate the safety and preliminary efficacy of AVB-101 in patients with FTD-GRN.
In the study, AVB-101 will be delivered as a one-time treatment into the thalamus via a stereotactic neurosurgical procedure at expert neurosurgical centers throughout Europe and the United States.
AVB-101 is an investigational gene therapy that contains a correct (non-mutated) version of the GRN gene. It is designed to restore levels of progranulin in the brain, potentially slowing or stopping the progression of FTD-GRN.
People between the ages of 30 and 75, diagnosed with FTD and a confirmed GRN mutation will be included in this study.
There are other criteria that determine eligibility, which may be discussed with a healthcare provider.
